← 返回前沿论文

免疫、年龄与管腔型乳腺癌:理解这神圣的三位一体

英文原题:Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity.

PubMed 2026/06/01(内容时间) Clin Cancer Res Q1 · IF 10.9(JCR 2025)

研究概要

在390名患有I至III期激素受体阳性/HER2-乳腺癌的患者中,较高数量的TIL(肿瘤浸润淋巴细胞)亚型,无论其具有免疫刺激还是免疫抑制特性,包括调节性T细胞、CD8和非CD8 T细胞,均与8年随访期间改善的无远处疾病生存期和总生存期相关。

中文摘要

在 390 例 I 至 III 期激素受体阳性/HER2 阴性乳腺肿瘤患者中,无论TIL(肿瘤浸润淋巴细胞)亚型具有免疫刺激还是免疫抑制作用,较高的 TIL 亚型数量(包括调节性 T 细胞、CD8 T 细胞及非 CD8 T 细胞)均与 8 年随访时更好的远处无病生存和总生存相关。

展开英文摘要原文

In 390 patients with stage I to III hormone receptor-positive/HER2- breast tumors, a higher number of tumor-infiltrating lymphocytes (TIL) subtypes, regardless of whether they were immunostimulatory or immunosuppressive, including regulatory T cells and CD8 and non-CD8 T cells, are associated with improved distant disease-free survival and overall survival at 8 years follow-up. See related article by Tesch et al., p. 2268.

论文信息

作者
Salgado R、Kok M
第一作者单位
Department of Pathology, ZAS Hospitals, Antwerp, Belgium.Belgium
通讯作者单位
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.Netherlands
期刊
Clinical cancer research : an official journal of the American Association for Cancer Research2026 Jun 1
原文标识
PubMed 41855142 · DOI 10.1158/1078-0432.CCR-25-4035